NKGen Biotech, Inc. and its subsidiary, NKGen Operating Biotech, Inc., entered into a Second Amendment to their Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited. The company received an additional loan of $412,500, which includes a $37,500 facilitation fee, resulting in net proceeds of $375,000. The new debt is documented by a Secured Convertible Promissory Note (Additional Note #2) convertible into common stock at $0.08 per share. The company issued an Additional Warrant #2 to the lender, exercisable for common stock at $0.08 per share for a ten-year period. The number of 'Consideration Shares' to be issued to the lender was increased to 12,147,280 shares, to be delivered in five installments over 25 months. A Voting Agreement was executed with key stockholders to ensure approval for an increase in authorized common stock to cover these issuances.